Logo of National Eczema Association mobile menu icon
Icon link to National Eczema's Instagram feed. Icon link to National Eczema's YouTube channel. Icon link to National Eczema's Facebook page. Icon link to National Eczema's Twitter feed. Icon link to National Eczema's inspire.com page. Search Icon to search the site

Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Clinical Trial Details for Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? The D-Vex Pilot Study

Murdoch Childrens Research Institute
NCT ID: NCT03257215
Last Updated: June 7, 2019

The Study at a Glance

  • Status: Recruiting
  • Phase: Phase 4
  • Gender: All
  • Age: 1 Year - 12 Years
  • Condition: Atopic Dermatitis
  • Study Type: Interventional
  • Intervention:
  • Lead Sponsor: Murdoch Childrens Research Institute
  • Location: Not Provided

Official Title

A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study


Vitamin D is known to have a regulatory influence on both the immune system and skin barrier function. Studies in paediatric populations have found an inverse association of vitamin D levels and with both prevalence and severity of atopic dermatitis (AD). Trials of vitamin D as a treatment for AD are limited in number and size. There has never been a placebo-controlled randomised controlled trial of stoss high dose versus daily standard dose for the treatment of AD. Further, no trials have explored the presence of vitamin D pathway genes and response to treatment of AD. This pilot study will be used as a reference to determine outcomes and feasibility for undertaking a larger and more in depth definitive study.


Ages Eligible for Study

1 Year to 12 Years

Sexes Eligible for Study


Accepts Healthy Volunteers

Accepts Healthy Volunteers


Inclusion Criteria:

– moderate to severe atopic dermatitis with a SCORAD ≥ 20 at baseline.

– aged between 1 ≤ 12 years of age at the time of randomisation.

– regularly ingest the recommended dietary intake (RDI) of calcium and plan to do so for
the next 3 months

– have a legally acceptable representative capable of understanding the informed consent
document and providing consent on the participant’s behalf.

Exclusion Criteria:

– use of vitamin D supplementation, including a stoss dose of vitamin D in the previous
year, or daily supplementation in the past month

– drink vitamin D fortified formula (all formulas) as the main milk intake

– received oral steroids within the past 6 months

– received oral immunosuppression in the past (cyclosporine, azathioprine, methotrexate)

– received UV therapy in the past 12 months

– have been fully formula fed within the past 6 months

– ave renal or liver or gastrointestinal (e.g.: coeliac, inflammatory bowel disease)

– receiving thiazide-type diuretics or anticonvulsant therapy

– have ever been diagnosed with Hypercalcaemia, Hypertension or Rickets

– unable to provide consent without the aid of an interpreter

– in the opinion of the Investigator, are unable to follow the protocol

Additional Information, Locations & Contacts

Sponsors & Collaborators

Murdoch Childrens Research Institute


Principal Investigator: Kirsten P Perrett, MBBS

Murdoch Children's Research Institute

Please refer to this study by its ClinicalTrials.gov identifier: NCT03257215



Royal Children's Hospital Melbourne

Melbourne, Victoria 3052


Kirsten P Perrett, MBBS